AAP
AVBP icon

Arax Advisory Partners’s ArriVent BioPharma AVBP Stock Holding History

Arax Advisory Partners’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9K Buy
574
+244
+74% +$7.2K ﹤0.01% 3964
2026
Q1 		$7.61K Buy
330
+139
+73% +$3.14K ﹤0.01% 2587
2025
Q4 		$3.84K Sell
191
-97
-34% -$2.02K ﹤0.01% 2991
2025
Q3 		$5.31K Buy
+288
New +$5.66K ﹤0.01% 2852
2025
Q1 		– Sell
-119
Closed -$3.17K – 3090
2024
Q4 		$3.17K Hold
119
– – ﹤0.01% 1894
2024
Q3 		$2.8K Hold
119
– – ﹤0.01% 1933
2024
Q2 		$2.21K Buy
+119
New +$2.12K ﹤0.01% 1934

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arax Advisory Partners's AVBP Position: Q2 2026 in Review

Arax Advisory Partners increased its ArriVent BioPharma (AVBP) stake by 74% in Q2 2026, buying an estimated $7.2K and bringing the position to 574 shares worth $19.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3964.

Arax Advisory Partners first reported a position in AVBP in Q2 2024 and has held it in 7 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Arax Advisory Partners held 574 shares of ArriVent BioPharma worth $19.9K as of Q2 2026.
  • Arax Advisory Partners bought 244 ArriVent BioPharma shares in Q2 2026, an estimated $7.2K.
  • ArriVent BioPharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3964 holding.
  • Arax Advisory Partners first reported a position in ArriVent BioPharma in Q2 2024 and has held it in 7 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.